...

June 09, 2015

UR Medicine’s Golisano Children’s Hospital has earned a place among the nation’s best hospitals in two pediatric specialty areas – nephrology and endocrine/diabetes – in U.S. News & World Report’s Best Children’s Hospital rankings.

The 2015-2016 rankings, released online Tuesday, placed nephrology at No. 41 and endocrinology/diabetes at No. 42 out of 184 pediatric institutions nationwide. Both specialties earned spots in the top 50 for the first time.

“We’re on the verge of opening a new children’s hospital, and now we’ve got another thing to celebrate,” said Mark Taubman, M.D., CEO of the University of Rochester Medical Center and Dean of the School of Medicine and Dentistry. “These divisions exemplify our focus on patient- and family-centered medicine, and we’re thrilled to be recognized nationally for the expert care that we provide.”

The Division of Pediatric Nephrology, which provides care for those with kidney disease and hypertension, has approximately 2,600 patient visits annually. Treating conditions such as hematuria, proteinuria, glomerulonephritis, fluid and electrolyte disorders, kidney stones, and kidney failure, the division has a team of six physicians, a pediatric nurse practitioner, and social worker, and over the past two years has added two new clinics for transplant screening and for premature babies with kidney problems who have graduated from the Neonatal Intensive Care Unit.

“We’ve really refined how we look at our patients on dialysis, and we’ve put extra effort into ensuring that our kidney transplant patients are getting their blood draws on a regular basis,” said George Schwartz, M.D., Chief of the Division of Pedatric Nephrology. “We have a great clinical group here.”

The Division of Pediatric Endocrinology, which includes a dedicated Diabetes Center, offers a full range of diagnostic, treatment, and consulting services for the approximately 6,000 patients it treats annually, the vast majority of whom are outpatients. Working closely with families, the division helps children with endocrine disorders maintain their normal at-home routines as much as possible.

Some of the most common conditions treated by the division include type 1 and 2 diabetes, hypothyroidism, hyperthyroidism, and Turner Syndrome. It has also combined efforts with colleagues in Gender Health Services, which offers a full spectrum of support to transgender youth and young adults. Made up of five physicians, three pediatric nurse practitioners, a psychologist, registered dietician, social worker, and new pediatric bone disease expert, the division offers the only multidisciplinary team of pediatric diabetes specialists in the Finger Lakes region.

“We have a wonderful group practice and have developed a system that works well for our families,” said Nicholas Jospe, M.D., Chief of the Division of Pediatric Endocrinology. “We provide good person-centered care for people with intercurrent problems, which is particularly important for diabetes.”

The U.S. News and World Report rankings feature the 50 best children’s hospitals in each of 10 pediatric specialties: cancer, cardiology and heart surgery, diabetes and endocrinology, gastroenterology, neonatology, nephrology, neurology and neurosurgery, orthopedics, pulmonology, and urology. Over the past four years, Golisano Children’s Hospital has appeared in the top 50 in six different categories.

The rankings will appear in the U.S. News Best Hospitals 2016 guidebook in September. 

For Media Inquiries:
Sean Dobbin
(585) 275-1171
This e-mail address is being protected from spambots. You need JavaScript enabled to view it

...

Rockwell Medical, Inc. shares have received a Mean Price Target of $17.83. According to the rating issued from 6 Wall Street Analysts, the High Price Target is seen at $27 while the Lower end of the Price Target is seen at $4. The Median Price Target is calculated at $17.5.

The stock has received coverage from different analysts. Oppenheimer initiates coverage on Rockwell Medical, Inc. (NASDAQ:RMTI) In a research note issued to the investors, the brokerage major a price-target of $24 per share.The shares have been rated Outperform.

The company has received recommendation from many analysts. 3 analysts have rated the company as a strong buy. 2 analysts have suggested buy for the company.1 analyst has also rated it as a strong sell.

Rockwell Medical, Inc. (NASDAQ:RMTI) rose 4.41% or 0.53 points on Monday and made its way into the gainers of the day. After trading began at $12.15 the stock was seen hitting $12.6 as a peak level and $11.78 as the lowest level. The stock ended up at $12.55. The daily volume was measured at 917,011 shares. The 52-week high of the share price is $12.47 and the 52-week low is $8.095. The company has a market cap of $630 million.

Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patients bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol.

...

Leslie Trigg is CEO of San Jose's Outset Medical, which makes a newly approved dialysis… more

Outset Medical, a San Jose company that makes dialysis equipment it says is far smaller and easier to use than the products of its rivals, has closed a dual-stage $91 million equity and debt financing round.

New investor Fidelity Research and Management Co. led a $51 million equity round, with help from prior investors Warburg Pincus and The Vertical Group as well as new investors Partner Fund Management LP, Perceptive Advisors and Capital Royalty Group.

CRG also led a $40 million debt financing.

Related Content

Bizspace Spotlight

This week's news expands on information Outset Medical disclosed May 21 in a regulatory filing. At the time, it said the Series B funding would raise $60 million, including $45 million in equity and $15 million in converted warrants.

CEO Leslie Trigg told me Monday that the complicated deal required a "two-stage close," with both stages now completed.

"Our plan is to ramp up commercialization pretty rapidly in the next couple of years," Trigg told the Business Times, adding that the $40 million in debt financing gives Outset "additional runway to power the business and invest in growth."

The market for such devices is estimated at $13 billion annually, says investor Warburg Pincus.

The company, which launched in 2010, has high hopes for its Tablo blood-filtering device, which at 35 inches tall and turquoise in color, is expected to be less intimidating to patients than traditional dialysis equipment.

It won Food and Drug Administration approval last fall for use in hospitals and dialysis clinics, Trigg said, along with a regulatory OK to do a investigational device exemption (IDE) trial to evaluate its safety and efficacy in the home setting.

Trigg said Outset is ramping up manufacturing of the device to support use in approved clinical settings.

Receive San Francisco Business Times's Morning Edition and Afternoon Edition newsletters and breaking news alerts.

...